Advertisement

Topics

FDA Approves Moxidectin For The Treatment Of River Blindness

09:20 EDT 14 Jun 2018 | Pharmaceutical Processing

The approval of moxidectin was based on data from two randomized, double blind, active controlled clinical studies.
Contributed Author: 
Medicines Development for Global Health

Original Article: FDA Approves Moxidectin For The Treatment Of River Blindness

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Moxidectin For The Treatment Of River Blindness"

Advertisement
Quick Search
Advertisement
Advertisement